Vaccine developer BiondVax shares soar

US health insurance co Elevance closing Israeli center

The rise in the share price was possibly related to a story about the company on Channel 1 TV news last night.

BiondVax Pharmaceuticals Ltd. (TASE:BNDX) saw its share price soar 15.77% today on the Tel Aviv Stock Exchange (TASE) to NIS 2.92.

The rise came without any announcements from the company. There is speculation that the rise was related to a story about the company on Channel 1 TV news last night. The item stressed the success of BiondVax's universal flu vaccine in first and second stage clinical trials.

Flu vaccine co BiondVax sees good Phase I/II results

Yorkville invests in Israel's BiondVax and MobileMax

BiondVax shares soar on positive flu vaccine report

BiondVax vaccine may be effective against swine flu

In the TV article, Prof. Ruth Arnon of the Weizmann Institute of Science, who developed the vaccine, and was also one of the developers of Copaxone, was interviewed. There were strong hints in the TV report that the vaccine will soon be commercialized, or there will be major investment in BiondVax, and it is thought that the report may have put the company on the radar screens of share investors.

Published by Globes [online], Israel business news - www.globes-online.com - on May 13, 2010